PACLITAXEL | N216338 | TEVA PHARMACEUTICALS INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | AstraZeneca | 594 | 2024-03-04 → 2026-10-14 | |
| Phase 3 | Active | National Cancer Institute (NCI) | 4,994 | 2007-11-02 → 2027-02-20 | |
| Phase 1 | Active | Toray Industries, Inc | 138 | 2019-04-26 → 2026-06 | |
| Phase 3 | Active | National Cancer Institute (NCI) | 184 | 2021-06-28 → 2030-08-15 | |
| Phase 2 | Active | SynerGene Therapeutics, Inc. | 28 | 2015-01 → 2026-12 | |
| Phase 2 | Active | Astellas Pharma Global Development, Inc. | 393 | 2019-03-15 → 2026-08-31 | |
| Phase 3 | Active | National Cancer Institute (NCI) | 692 | 2010-09-27 → 2026-07-02 | |
| Phase 1 | Active | Washington University School of Medicine | 12 | 2019-11-07 → 2029-11-20 | |
| N/A | Active | TriReme Medical, LLC | 333 | 2017-07-26 → 2026-12 | |
| N/A | Active | Memorial Sloan Kettering Cancer Center | 110 | 2016-10 → 2026-10 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
Lowest Price
$584.83
Highest Price
$1003.02
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 00480-3290-01PACLITAXEL PROTEIN-BOUND 100MG/VIL INJ | $584.83 | Big4 | Teva Pharmaceuticals USA, Inc. | 04/30/2026 |
| 00480-3290-01PACLITAXEL PROTEIN-BOUND 100MG/VIL INJ | $1003.02 | FSS | Teva Pharmaceuticals USA, Inc. | 04/30/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
18 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Nov 24, 2023 | SUPPL -1 | View Letter (PDF) |
| May 12, 2023 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.